Juvenile onset systemic lupus erythematosus: a possible role for vitamin D in disease status and bone health


Autoria(s): Casella, C. B.; Seguro, L. P. C.; Takayama, L.; Medeiros, D.; Bonfa, E.; Pereira, R. M. R.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

14/08/2013

14/08/2013

2012

Resumo

Purpose: In juvenile onset systemic lupus erythematosus (JoSLE), evidence for the association between vitamin D status, lupus activity, and bone health is very limited and not conclusive. The aim of this study was, therefore, to assess in JoSLE patients the possible relevance of vitamin D deficiency in disease and bone parameters. Methods: Fifty-seven JoSLE patients were initially compared to 37 age, race and body mass index (BMI) -matched healthy controls. The serum concentration of 25 hydroxyvitamin D (25OHD) was determined by radioimmunoassay. Patients with 25OHD deficiency (acurrency sign20 ng/mL) were compared to those with levels > 20 ng/mL. Disease activity was evaluated by SLE Disease Activity Index (SLEDAI). Bone mineral density (BMD) and body composition (BC) were measured using dual-energy X-ray absorptiometry (DXA). Results: 25OHD levels were similar in patients and controls (21.44 +/- 7.91 vs 22.54 +/- 8.25 ng/mL, p = 0.519), regardless of supplementation (65% of patients and none in controls). Thirty-one patients with 25OHD deficiency (acurrency sign20 ng/mL) were further compared to the 26 JoSLE patients with levels > 20 ng/mL. These two groups were well-balanced regarding vitamin D confounding variables: age (p = 0.100), ethnicity (p = 1.000), BMI (p = 0.911), season (p = 0.502), frequency of vitamin D supplementation (p = 0.587), creatinine (p = 0.751), renal involvement (p = 0.597), fat mass (p = 0.764), lean mass (p = 0.549), previous/current use of glucocorticoids(GC) (p = 1.0), immunosuppressors (p = 0.765), and mean current daily dose of GC (p = 0.345). Patients with vitamin D deficiency had higher SLEDAI (3.35 +/- 4.35 vs 1.00 +/- 2.48, p = 0.018), lower C4 levels (12.79 +/- 6.78 vs 18.38 +/- 12.24 mg/dL, p = 0.038), lower spine BMD (0.798 +/- 0.148 vs 0.880 +/- 0.127 g/cm2, p = 0.037) and whole body BMD (0.962 +/- 0.109 vs 1.027 +/- 0.098 g/cm2, p = 0.024). Conclusion: JoSLE vitamin D deficiency, in spite of conventional vitamin D supplementation, affects bone and disease activity status independent of therapy and fat mass reinforcing the recommendation to achieve adequate levels. Lupus (2012) 21, 1335-1342.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/08312-3]

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [301411/2009-3, 300559/2009-7]

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico

Federico Foundation

Federico Foundation

Identificador

LUPUS, LONDON, v. 21, n. 12, supl. 1, Part 1, pp. 1335-1342, OCT, 2012

0961-2033

http://www.producao.usp.br/handle/BDPI/32553

10.1177/0961203312454929

http://dx.doi.org/10.1177/0961203312454929

Idioma(s)

eng

Publicador

SAGE PUBLICATIONS LTD

LONDON

Relação

LUPUS

Direitos

openAccess

Copyright SAGE PUBLICATIONS LTD

Palavras-Chave #VITAMIN D #JUVENILE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS #DISEASE ACTIVITY #BONE MINERAL DENSITY #BODY COMPOSITION #GLUCOCORTICOID-INDUCED OSTEOPOROSIS #25-HYDROXYVITAMIN D LEVELS #X-RAY ABSORPTIOMETRY #D ENDOCRINE SYSTEM #D DEFICIENCY #AUTOIMMUNE-DISEASES #1,25-DIHYDROXYVITAMIN D-3 #RHEUMATOID-ARTHRITIS #CARDIOVASCULAR-DISEASE #PREMENOPAUSAL WOMEN #RHEUMATOLOGY
Tipo

article

original article

publishedVersion